Department of Pharmacology, School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, China.
Department of Chemical Biology, School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, China.
Nanomedicine (Lond). 2024;19(18-20):1585-1600. doi: 10.1080/17435889.2024.2365623. Epub 2024 Jul 16.
A multifunctional nanoplatform has been developed to enhance the targeting capability and biosafety of drug/siRNA for better diagnosis and treatment of myocardial infarction (MI). The nanoplatform's chemical properties, biodistribution, cardiac magnetic resonance imaging (MRI) capabilities, therapeutic effects and biocompatibility were investigated. The nanoplatform exhibited MI-targeting properties and pH-sensitivity, allowing for effective cardiac MRI and delivery of drugs to the infarcted myocardium. The GCD/Qt@ZIF-RGD demonstrated potential as a reliable MRI probe for MI diagnosis. Moreover, the GCD/si-SHP1/Qt@ZIF-RGD effectively suppressed SHP-1 expression, increased pro-angiogenesis gene expression and reduced cell apoptosis in HUVECs exposed to hypoxia/reoxygenation. Our newly developed multifunctional drug delivery system shows promise as a nanoplatform for both the diagnosis and treatment of MI.
已经开发出一种多功能纳米平台，以增强药物/siRNA 的靶向能力和生物安全性，从而更好地诊断和治疗心肌梗死 (MI)。研究了纳米平台的化学性质、生物分布、心脏磁共振成像 (MRI) 能力、治疗效果和生物相容性。该纳米平台表现出 MI 靶向特性和 pH 敏感性，能够有效进行心脏 MRI 并将药物递送到梗死的心肌中。GCD/Qt@ZIF-RGD 有望成为 MI 诊断的可靠 MRI 探针。此外，GCD/si-SHP1/Qt@ZIF-RGD 可有效抑制 HUVECs 暴露于缺氧/复氧时 SHP-1 的表达，增加促血管生成基因的表达，减少细胞凋亡。我们新开发的多功能药物递送系统有望成为 MI 诊断和治疗的纳米平台。
